However, the propensity for this disease to rapidly metastasize and the inability to improve patient outcomes, despite efforts aimed at early detection
, Francisco X. Real 14 , Sean P. Cleary 15, 16 , Michael H. Roehrl 3, 9 , John D. McPherson 1, 4 , Lincoln D. Stein 1, 6 , Thomas J. Hudson 1, 6 , Peter J. Campbell 2, 17 & Steven Gallinger 1, 15, 16 Pancreatic cancer, a highly aggressive tumour type with uniformly poor prognosis, exemplifies the classically held view of stepwise cancer development 1 . The current model of tumorigenesis, based on analyses of precursor lesions, termed pancreatic intraepithelial neoplasm (PanINs) lesions, makes two predictions: first, that pancreatic cancer develops through a particular sequence of genetic alterations 2-5 (KRAS, followed by CDKN2A, then TP53 and SMAD4); and second, that the evolutionary trajectory of pancreatic cancer progression is gradual because each alteration is acquired independently. A shortcoming of this model is that clonally expanded precursor lesions do not always belong to the tumour lineage 2, [5] [6] [7] [8] [9] , indicating that the evolutionary trajectory of the tumour lineage and precursor lesions can be divergent. This prevailing model of tumorigenesis has contributed to the clinical notion that pancreatic cancer evolves slowly and presents at a late stage 10 . However, the propensity for this disease to rapidly metastasize and the inability to improve patient outcomes, despite efforts aimed at early detection 11 , suggest that pancreatic cancer progression is not gradual. Here, using newly developed informatics tools, we tracked changes in DNA copy number and their associated rearrangements in tumour-enriched genomes and found that pancreatic cancer tumorigenesis is neither gradual nor follows the accepted mutation order. Two-thirds of tumours harbour complex rearrangement patterns associated with mitotic errors, consistent with punctuated equilibrium as the principal evolutionary trajectory 12 . In a subset of cases, the consequence of such errors is the simultaneous, rather than sequential, knockout of canonical preneoplastic genetic drivers that are likely to set-off invasive cancer growth. These findings challenge the current progression model of pancreatic cancer and provide insights into the mutational processes that give rise to these aggressive tumours.
Pancreatic cancer will be the second leading cause of cancer-related death in a decade and the biological basis for the aggressive nature of this disease is largely undefined. Motivated by this, we explored the pancreatic cancer genome to address this concern. These genomes are highly unstable 13 , as evidenced by the marked modifications to the DNA copy number landscape. Although this instability is further exacerbated with metastatic progression 14 , it remains unclear when the instability begins relative to the key genetic alterations that give rise to the invasive clone. Also, whether this instability propagates through single copy number changes that accumulate one after another or through large numbers of concurrent changes has not been fully addressed. These questions have important basic and translational implications. As a first step, the mechanisms at the root cause of this instability need to be identified. Mutational phenomena such as chromothripsis and polyploidization have been linked to unstable tumours 15, 16 and aggressive tumour behaviour 17 , indicating that they play a role in pancreatic cancer development. These particular phenomena are considered to accelerate cancer evolution because the DNA damage that ensues from such mitotic errors must be resolved in one or few rounds of cell division; otherwise the cell would die. To date, the extensive fibrosis in pancreatic cancer has obstructed the sequencing resolution needed to clearly decipher these events. In this study, we performed an in-depth analysis of more than 100 whole genomes (Extended Data Fig. 1 ) from purified primary and metastatic pancreatic tumours (referring to ductal adenocarcinoma only), focussing on the mutational phenomena linked to rapid tumour progression.
To evaluate polyploidization, we developed and validated a new informatic tool, termed CELLULOID, which estimates tumour ploidy and copy number from whole-genome data ( Fig. 1a and Extended Data Fig. 2 ). We found that 45% (48/107) of tumours displayed changes in copy number consistent with polyploidization (ploidy solutions can be found in Supplementary Information). Of the polyploid tumours, 88% (42/48) were tetraploid and the rest were hexaploid. The mean ploidy of diploid tumours was 1.95, whereas those tumours that underwent genome duplication and triplication was 3.38 and 5.40 (relative to 4 and 6), indicating that a larger proportion of the genome was lost in the latter subgroup (Extended Data Fig. 3a, b) , consistent with previous data 16 . Polyploid tumours had higher incidences of mutation in TP53 (P = 0.02, Fisher's exact test; Extended Data Fig. 1e ) and harboured 1.5-fold more copy number alterations compared to diploid tumours (median value of 112 versus 77, P = 0.003, t-test; Extended Data Fig. 3c ).
The marked loss of genomic material relative to baseline ploidy and increased amount of copy number alterations in polyploids demonstrates that these genomes are highly unstable.
We then used mutation data to infer the timing of the polyploidization event in tumour evolution (Supplementary Results). All cases were first categorized according to their dominant mutational signature, since specific aetiologies drive mutation accrual 18 . Two subgroups were evident: one where C > T transitions dominated, linked to the process of cytosine deamination (approximately 80% Age-related, Extended Data Fig. 3d ) and another where all six classes of base substitutions were more-or-less balanced-a phenomenon associated with defects in double-strand break repair (DSBR, 17%; Extended Data Fig. 3d) . Accordingly, half of the DSBR cases carried germline or somatic mutations in BRCA1/2 (ref. 13 ). The remaining cases were comprised of heterogeneous signatures previously identified by Alexandrov et al. 18 (Extended Data Fig. 3d ).
We found that most mutations preceded polyploidization in both mutational subgroups (Fig. 1b) . By contrast, most copy number losses and gains occurred after polyploidization, an effect that was markedly magnified when the size of the copy number change was taken into account (losses: P = 4.3 × 10 −7 ; gains: P = 0.003, t-test; Fig. 1c and Extended Data Fig. 3e ). This implies that changes in copy number that precede polyploidization were smaller and focal whereas those that come after are larger and more structurally damaging to the genome. Some of these larger changes are likely to be a consequence of the improper segregation of chromosomal material gained during polyploidization. Copy number alterations corresponding to the polyploidization event were commonly seen at integer values and indicate that such events are mostly or fully clonal (CELLULOID solutions in Supplementary Information). Two conclusions emerge from these data: first, polyploidization occurs after an extended diploid phase of mutation accrual; and second, changes in copy number related to polyploidization come to rapidly dominate in the tumour within a shorter timeframe, suggesting they are relevant to disease progression.
Many diploid and polyploid tumours harboured focal copy number alterations that oscillated between a few DNA copy-states, characteristic of chromothripsis 15 . We developed a sensitive algorithm, termed ChromAL (see Methods and Supplementary Results), to differentiate chromothripsis from localized gradual events that accumulate over time. We found that 65.4% (70/107) of tumours harboured at least one chromothripsis event (solutions provided in Supplementary Information). A similar frequency was observed in an independent genome cohort (60%, n = 50 out of 84, Supplementary Results). Of all chromothripsis events, 11% occurred on chromosome 18 (Extended Data Fig. 4a ), resulting in the loss of the key tumour suppressor gene SMAD4. By comparing the consensus copy number profiles of tumours with and without chromothripsis, we found that SMAD4 loss was accompanied by a gain in a region of chromosome 18 that harbours GATA6, an oncogene implicated in pancreatic cancer development (Extended Data Fig. 4b , top panel and Supplementary Fig. 1 ). Furthermore, 8% of events were observed on chromosome 12. The consensus copy number profile of these cases revealed a focal amplification in the region of KRAS (Extended Data Fig. 4b , middle panel). These amplifications commonly affected the mutant KRAS allele either directly, when chromothripsis and breakage-fusion-bridge (BFB) cycles were combined (Extended Data Fig. 4c , tumour Pcsi_0290), or indirectly, when polyploidization was subsequent to a chromothripsis event that removed the wild-type copy (Extended Data Fig. 4c,  Pcsi_0356 ). There was significantly more chromothripsis in polyploid tumours than in diploid tumours, confirming the greater genetic instability in the former subgroup (P = 0.013, Fisher's exact test; Extended Data Fig. 4d ). We observed worse overall survival in patients whose tumours had such an event (P = 0.025, log-rank test; Supplementary  Fig. 2 ). The high prevalence of chromothripsis in pancreatic cancer, together with previously established links between chromothripsis and aggressive tumour behaviour in other cancers 15, 17 , strongly implicate this mutational processes as a key part of pancreatic cancer development. Notably, these data directly support the 'catastrophic' model of pancreatic cancer progression proposed by Real 19 more than a decade ago. We next performed a series of focused analyses, using individual tumours to illustrate the broad principles of the approach applied to the genome cohort. The data presented above raises an important question: how much of the overall genetic instability in these tumours can be attributed to a single chromothripsis event? In Pcsi_0082, a tetraploid tumour, 63% of all copy number alterations could be attributed to five Cases were segregated based on mutational signature subtype: DSBR (n = 5; left) and age-related (n = 32; right). Owing to the increased genetic instability in polyploid cells, mutations in regions of copy number of 4 in tetraploids were used in this analysis. c, Fraction of the genome lost and gained either before (yellow) or after (blue) polyploidization. Box and whisker plots depict median and 10-90 percentile ranges. P values are indicated and were derived using a t-test. A detailed description of these data is given in Supplementary Results. distinct chromothripsis events, on chromosomes 8, 13, 15, 16 and 18 (Extended Data Fig. 5a ). As chromothripsis is sustained and resolved in a single cell-division cycle 20, 21 , we can approximate that more than half of the genomic damage in Pcsi_0082 was incurred from approximately five aberrant mitoses. Because Pcsi_0082 had undergone polyploidization, we were able to infer the timing of chromothripsis events relative to the genome doubling using the magnitude of the copy number changes. As chromothripsis occurs on one copy of DNA, the events sustained on chromosomes 13, 16 and 18 must have occurred after polyploidization because the copy number changes on these chromosomes mostly vary by one (Extended Data Fig. 5a , events 2, 4 and 5). By contrast, the chromothripsis on chromosomes 8 and 15 occurred while the tumour was still diploid, since these copy number changes vary in multiples of two, a result of genome doubling (Extended Data Fig. 5a , events 1 and 3). Across all polyploid tumours, we observed that more than half (59%) of all chromothripsis events transpired before polyploidization (ChromAL solutions). This suggests that polyploidization further exacerbates the pre-existing genetic instability in these tumours. Overall, many copy number alterations in pancreatic cancer are acquired through rapid bursts of genetic change from a single or few mitotic events (Extended Data Fig. 5b ) rather than a set of gradual events that accumulate over time.
To investigate the role of these mitotic events in disease progression, we analysed the genomes of 15 distinct metastases from six patients (Extended Data Fig. 6 and Supplementary Results). In one case of fulminant metastatic progression (Pcsi_0410), eight distinct metastases were sequenced (Fig. 2a shows the progression timeline). All metastases were polyploid and also carried two distinct chromothripsis events, one on chromosome 6 and another on chromosome 8, that resulted in the marked amplification of MYC (20-40 copies), resembling a double minute (Fig. 2b , c and Extended Data Fig. 7a ). The final copy number in areas of loss of heterozygosity (LOH) in both chromothripsis events is two, indicating that both chromothripsis events occurred before polyploidization (Extended Data Fig. 7b ). Using fluorescence in situ hybridization (FISH), we confirmed that the primary tumour was also polyploid and harboured chromothripsis ( Fig. 2c and Supplementary  Fig. 3a, b) . Thus, we can infer that both chromothripsis events preceded polyploidization and that the systemic spread of the disease occurred after polyploidization by a clone that harboured all three mitotic events (Fig. 2d ). An additional chromothripsis event was detected on chromosome 13 in the adrenal gland metastasis ( Supplementary  Fig. 3c ), consistent with previous data on ongoing genetic instability with metastatic progression 14 . Overall, we observed that chromothripsis was maintained in metastases if it was present in the primary tumour (Extended Data Fig. 6d ). These data support the notion that the majority of genetic instability precedes metastases and is fostered early in tumorigenesis. If the dominant clonal lineage of the primary tumour arises from these types of mitotic events, it suggests that intra-tumoural heterogeneity in pancreatic cancer 10 follows this event, akin to the 'big-bang' model proposed for colon cancer 22 . The central tenet of the PanIN progression model posits that alterations in KRAS, CDKN2A, TP53 and SMAD4 are acquired as part of a consecutive series of events in tumour evolution. To directly test this model, we used DNA rearrangements to reconstruct the evolutionary history of allelic losses of tumour suppressors based on evidence that allelic alterations are early events in tumorigenesis (Supplementary Results and Luttges et al. 5 ). Ashpc_0005, a tetraploid tumour, had a complex pattern of rearrangements involving chromosomes 9, 17 and 18, where CDKN2A, TP53 and SMAD4 are found (Fig. 3a) . Several features of this rearrangement pattern facilitate the reconstruction of (2) lu (1) lu (2) . c, FISH analysis of MYC amplification in primary tumour and all metastases. ctr, control (fibroblasts). d, Left, the proportion of structural variants common to all (black), shared by two or more (blue), or unique to each metastasis is shown. Right, copy numbers and structural variants were used to reconstruct phylogenetic tree of metastatic progression. The primary tumour was surgically removed one year before autopsy and fresh-frozen material was not available for whole-genome sequencing. It is possible that branch lengths of the phylogenetic tree would vary if the primary tumour were included in this analysis. Lines are to scale with the copy-number-based clustering dendrogram presented in Supplementary Fig. 15 , with the exception of germline origin (GL), which is half the length.
the mutational events in this tumour. First, there are two independent sets of rearrangements on chromosome 9 that flank CDKN2A (Fig. 3b , windows 1 and 2), indicating that the two copies of this gene were lost as part of independent chromothripsis events. Second, there are distinct amplified DNA segments in window 2 ( Fig. 3c) that are bounded by a specific type of rearrangement referred to as a fold-back inversion, an alteration that leaves behind steep copy number drops (>2) indicative of a cycle of BFB 14 . Three steep copy number drops in window 2 are evidence of three cycles of BFB (Fig. 3c) . Third, the intervening change in copy number (from 10 to 8) on one of these amplified segments suggests that a chromothripsis event followed three cycles of BFB and was likely to be the final major event that stabilized the derivative chromosome 23 ( Fig. 3c, penultimate panel) . Fourth, all copy number changes in the event are in multiples of two, indicating that polyploidization followed the BFB cycles and chromothripsis (Fig. 3a) . Finally, the copy number change on chromosome 18 from 3 to 1 (rather than 4 to 2) indicates that one wild-type copy of this chromosome was lost after polyploidization (Fig. 3a) . The relative order of the first and the second copy losses of CDKN2A cannot be deciphered, but a single event involving BFB and chromothripsis knocked out a single copy of CDKN2A, TP53 and SMAD4 in synchronized fashion (Fig. 3d, e) . Using rearrangements to reconstruct the sequence of events in a second case (Pcsi_0171) demonstrated that a single chromothripsis event simultaneously knocked out CDKN2A and SMAD4 (Extended Data Fig. 8) . Notably, rearrangement patterns in 16% of cases (17/107) combined allelic alterations in KRAS, CDKN2A, TP53 and SMAD4 genes, predominantly as double knockouts (14% if only tumour-suppressor genes are considered; Supplementary Fig. 4) . In a proof-of-principle experiment using single-cell sequencing in a tumour where rearrangements did not span these genes, we found an ancestral clone that harboured a SMAD4 loss but retained TP53 and CDKN2A (Extended Data Fig. 9 ). These data provide direct evidence that a number of cases do not conform to the accepted mutational hierarchy predicted by the PanIN progression model and warrant future investigation into the sequence of mutational events that give rise to these aggressive tumours.
Studies dating back two decades have been critical in moulding the current perspective of how pancreatic cancer develops 1 . Key features of our data provide a framework to broaden this view. First, analysis of polyploid tumours revealed that most mutations accumulate when these tumours are still diploid. Assuming that preneoplastic cells are diploid, a fraction of these mutations must be preneoplastic. Zigzag symbol indicates DNA double-strand break to initiate BFB. d, Temporal order of events based on rearrangement profile. The leftover TP53 and SMAD4 alleles carry inactivating mutations (x). As both TP53 alleles carry the mutations (ploidy > 1), this mutation was acquired before genome duplication. Relative timing of the SMAD4 mutation cannot be inferred because there is only one copy of this allele and the mutation is fully clonal. d(8;9), d(9;18) and d (9, 17, 18) refer to candidate derivative chromosomes based on DNA rearrangement profiles. e, Summary of tumour evolution in Ashpc_0005. WGD, whole-genome duplication.
non-invasive 24 . This suggests a prolonged preneoplastic phase predates the onset of invasive disease and that copy number events are crucial for transformation (Extended Data Fig. 10 ). These data carry implications for the design of future studies on the early detection of pancreatic cancer 11 . Second, copy number changes from chromothripsis are essentially clonal, suggesting that these events are sustained early in tumorigenesis. The inactivation of well-known preneoplastic drivers (CDKN2A, TP53, SMAD4) en bloc strongly supports this notion and implies that chromothripsis can be a transforming event under the right gene context 17, 23 . Our data also raise the possibility that some pancreatic cancers may not progress through a linear series of PanIN lesions 19 . Why catastrophic mitotic phenomena are so frequent in pancreatic cancer cannot be easily answered. Perhaps the extensive fibrosis in these tumours, known to suppress tumour development 25, 26 , apply a selective pressure that favours punctuated events over gradual ones. Lastly, pancreatic cancer is well known for its proclivity to metastasize. In mouse models of pancreatic cancer, genetic instability contributes to metastatic progression 27 . If chromothripsis is indeed the transforming event in some tumours, as our data suggest, a single event could thus confer a cell with both invasive and metastatic properties. In this scenario, there would be a very short latency period between the birth of the invasive clone and the ability of that clone to metastasize 28, 29 . This supposition is consistent with the observation that 80% of pancreatic cancer patients present with advanced disease at diagnosis. How these mutational processes contribute to disease progression and metastatic phenotype is therefore a critical topic of investigation; such knowledge will be essential to guide more effective screening and therapeutic strategies, both for pancreatic cancer and other aggressive tumour types.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
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METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Ethical approval and sample acquisition. A total of 107 surgically resectable samples of pancreatic ductal adenocarcinoma tissue were obtained from collaborating hospitals in Canada and the United States from patients that gave informed consent under the ICGC protocol. 84 samples were obtained from the University Health Network (Toronto, Canada), 14 samples from the Mayo Clinic, 3 samples from the University of Nebraska as part of a rapid autopsy program, 5 samples from Sunnybrook Health Sciences Centre (Toronto, Canada), and 1 sample from McGill University (Montreal, Canada). Consent for WGS was obtained locally at each institute. At the Ontario Institute for Cancer Research, approval was obtained through the University Health Network Research Ethics Board (08-0767-T) and University of Toronto Research Ethics Board (30024). Pre-operatively, blood samples were collected for germline DNA. Where blood was not collected, duodenal mucosa or other non-cancerous tissue was collected post-operatively to obtain germline DNA. Tumours were sectioned to confirm the diagnosis of ductal adenocarcinoma and pieces were snap-frozen in liquid nitrogen and stored at −80 °C or −150 °C before proceeding with laser capture microdissection (LCM). For 21 cases (17 UHN, 4 Sunnybrook), fresh tumour material was dissociated and viably sorted at −150 °C (below). We obtained clinical follow-ups on the majority of cases. Sample dissociation and cell sorting. Freshly resected tumours were minced into fine pieces in 10-cm tissue culture dishes using a razor blade. After mechanical dissociation, 9 ml of RPMI supplemented with 1% FBS was added. 1 ml of 10× collagenase/hylauronidase mix (Stemcell technologies) was added to bring the volume to 10 ml and the sample was placed in a 37 °C incubator. Every 20 min, the tissue pieces in the culture dish were pipetted through narrowing orifices (for example, a 10 ml then 5 ml then 1 ml pipette) for a total of 60-120 min. The sample was then passed through a 70-150-μm nylon mesh, centrifuged and resuspended in DMSO (Sigma) based cryopreservation media (20% FBS/10% DMSO final) and placed at −150 °C for long-term storage. . After thawing, cells were spun at a low r.p.m. (~1,000) for 20 min at 4 °C. After spinning, the thawing solution was removed and cells were resuspended in 100 μl of PBS + 5% FBS for antibody staining and cell sorting. The following antibodies were used for cell sorting: GlyA FITC (BD bioscience, clone HIR2), CD140b PE (BD bioscience, clone 28D4), CD45 PC5 (Beckman Coulter, clone IM1833), EpCAM PerCP-eFluor710 (eBioscience, clone 1B7), CD31 PC7 (eBioscience, clone WM-59), CD90 (BD Biosciences, clone 5E10), CD34 APC7 (BD bioscience, clone 581, custom conjugation). Cell sorting was performed on the BD FACSAria III using 4-laser configuration. Laser capture microdissection. Snap-frozen tumour tissue embedded in optimal cutting temperature compound was cut into 8 μm sections and mounted on PEN-Membrane Slides (Leica). Sections were stained with diluted haematoxylin to distinguish tumour epithelium from stroma. A staff pathologist marked tumour sections and LCM was performed according to manufacturer's protocol on the Leica LMD7000 system. Specimens were collected by gravity, contact-free and contamination-free, and directly placed in DNA lysis buffer.
Whole-genome sequencing was performed on DNA from tumour-enriched material. Details of sequencing protocols are included in the Supplementary Methods. CELLULOID: evaluation of tumour cellularity, tumour ploidy, and absolute copy number profiles. After alignment, reads are counted in 1-kb bins using functions from the R package 'HMMcopy' . These counts are then adjusted for the GC content of each bin using LOESS (local) regression and scaled to the mean (scaled GC-corrected read count (SRC)). Segmentation of the data in both tumour and normal tissue (say, from matched non-malignant tissue or from blood) is performed using penalized least squares, as implemented in the R package 'copynumber' . Each segment is assigned the mean SRC value, which is calculated from the bins within the segment. SRC is proportional to the mean number of chromosomes (copies), averaged over all sequenced cells.
Germline heterozygous positions are extracted in the autosome, except in regions of the genome where duplication or deletion events are observed in the normal tissues. The number of reads supporting each allele (the reference allelethe one observed on the reference human assembly-and the alternate allele) is recorded from the tumour data and the allelic ratio (AR; the proportion of reads supporting the reference allele) calculated. Each heterozygous position is also paired with the SRC value of the segment it belongs to, evaluated from the tumour data, to form pairs of values (SRC, AR). These pairs of points are represented in a three-dimensional graph as a contour (elevation) plot (Fig. 1) . This figure is a visual representation of the autosomal-wide copy-number profile of the tumour. Each peak (or pair of peaks since the graph is reflected around AR = 0.5) corresponds to a specific copy number state that summarizes both the total copy number (on the x axis, once appropriately scaled) and the ratio of relative abundance of maternal and paternal copies (on the y axis, once contamination from normal tissues-or tumour cellularity-is accounted for). The relative positions of these peaks can be mathematically derived in the following way.
Let us define the autosomal ploidy of a sequenced sample (that includes both tumour and possibly contamination from normal cells) as:
where c b represents the mean number of chromosomal copies at base b, averaged over all cells, and N B is the number of autosomal bases. This can be interpreted as the relative abundance of autosomal DNA in the sequenced sample compared to a normal (reference) haploid autosomal genome. We aim to use the SRC values to estimate the ploidy. Re-writing the above as:
(where K is a scaling constant) is not informative since the SRC values are scaled and relative, making this expression trivial. However, because SRC are scaled to the mean, bins that fall in regions of exactly P copies (averaged over all cells) are expected to display SRC values of 1. Let S be the value of SRC that would be expected in regions where all cells display 2 copies of chromosomes (such regions do not need to actually exist in the sequenced sample). Because of proportionality, we have the relationship:
thus, ploidy can be evaluated by finding S.
Consider the more general case of a sequenced sample that consists of a proportion n of normal cells and t of tumour cells (n + t = 1). Because ploidy may differ in normal and tumour cells, these percentages are not equivalent to percentages of reads originating from normal or tumour cells. Consider a segment in the genome that is present in 2 copies in the normal cells and an average of T copies in the tumour cells. The tumour cells can be further broken down in subclones, in proportions t 1 , t 2 , …(t = t 1 + t 2 + …), each subclone displaying a different number of copies (T 1 , T 2 , …). Then, by proportionality, the SRC of bins in that segment are expected to take the value:
To determine the expected AR of heterozygous positions in that segment, the number of copies need to be further broken down into number of maternal and paternal copies: T i = M i + P i . Normal cells are assumed to have one maternal chromosome and one paternal chromosome. In a segment that displays M i maternal and P i paternal copies in subclone i, the AR is expected to take the value: if, say, the maternal chromosome carries the reference allele, and reflected around 0.5 otherwise. Let:
represent the (x, y) coordinates described in equations (1) and (2). Let OP = {OP i } be the set of observed contour plot peaks (or subset of peaks deemed of particular interest by the user). The algorithm used to estimate S, n and t finds parameters that minimize the total distance between the observed peaks and the expected peak (EP) coordinate closest to each. In other words, if:
min OP EP( , , , , , , , ) , then the algorithm consists on finding S, n and t that minimize:
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In practice, the number of expected peak locations grows exponentially with the number of subclones and the number of maternal/paternal configurations. The algorithm further depends on a set of allowed copy number configurations (a set of M i and P i ) that can be set by the user. For example, the user might want to ignore configurations where the number of maternal chromosomes is smaller than the number of paternal chromosomes in one subclone but higher in another; this would reduce the number of possible ARs. Other restrictions may include situations where the number of copies between different subclones cannot differ (by difference or by ratio) by more than some specified threshold.
The objective function to be minimized is not convex and multiple local minima exist. Optimization is done either by simulated annealing if a global minimum is desired (using the R package GenSA) or using the R built-in function 'optim' with grid-defined starting points to survey and inspect a set of local minima.
Once values for S, n and t are obtained, the ploidy in the tumour cells (P T ) can then be calculated as:
where P = 2/S is the ploidy of the whole sample that was sequenced. The SRC values can be rescaled into their corresponding integer copy number in tumours using equation 1 above.
The above describes the current implementation of an R package named CELLULOID, which can be obtained from http://github.com/mathieu-lemire. Chrom-AL: detecting catastrophic mitotic events. Chrom-AL is an in-house tool developed to standardize the detection of complex rearrangement patterns linked to chromothripsis 20 . Chrom-AL applies a series of statistical tests and thresholds at the level of the chromosome and also within the windows of the structural events to infer a call. We inspected 80 genomes manually and estimate that the false-positive and false-negative rate of Chrom-AL is ~7% and ~8%, respectively, in our dataset. The tool is designed based on the chromothripsis criteria presented by Korbel and Campbell 30 . Complex rearrangement patterns can often involve multiple distinct types of mitotic errors (for example, FoSTeS, MMBIR) including a chromothripsis event 20, 21, 23 . Chrom-AL is not designed to distinguish chromothripsis from other replication-based mitotic errors, which can also be catastrophic within one or few cell divisions. As such, we use the term chromothripsis to broadly refer to a 'oneoff ' mitotic catastrophe.
As chromothripsis events typically increase the number of structural variants in a genome, there is a correlation between tumours with increased numbers of structural variants and rate of chromothripsis. Thus, proper structural variant calling becomes a critical parameter in implementation of any algorithm to call chromothripsis. Despite this correlation, a high rate of structural variants does not necessarily imply a chromothripsis event. Thus, the false-positive and falsenegative rates of Chrom-AL will probably vary with the overall rate of structural variants that differs amongst tumour types. For this reason, visual inspection still remains a critical tool in evaluating such events. Chrom-AL does not detect chromothripsis events that are predominately driven by a single type of structural variation. For example, on rare occasions we observed the typical copy number oscillation hallmark of chromothripsis that was connected mostly by head-tohead (HH) or tail-to-tail (TT) inversions. Whether such rearrangements were indeed accumulated over time or all at once is not known. To remain consistent with the criteria discussed below, we excluded these events from the analysis. Below, we describe the criteria and conditions used to detect cataclysmic events by Chrom-AL. Chrom-AL was implemented in R. Threshold for number of structural variants and copy number alterations at the (chromosomal level); test 1. Catastrophic events typically have large numbers of structural variations and copy numbers changes. Only events with at least 7-8 structural variants and 8 copy number segments were considered in the analysis. Clustering of break points (chromosomal level); test 2. Catastrophic events are typically localized to particular genomic regions that can be assessed statistically. To do this, we ordered the break points sequentially and calculated the distances between each break point. The distribution of distances was compared against the exponential distribution as described by Korbel and Campbell 30 using a Kolmogorov-Smirnov (KS) test and followed by Bonferroni correction. Regions with a q ≤ 0.1 were considered to display evidence of break-point clustering. Chromosomal break-point enrichment (chromosomal level); test 3. We observed several instances where structural variants comprising a catastrophic event were scattered chromosome-wide and did not cluster within a particular region of a chromosome. Thus, they failed the KS test described above. To account for this shortcoming, we performed an additional test to determine if structural variants were enriched on any particular chromosome than would be expected by chance. To identify chromosomes enriched for structural variants, a hypergeometric test was run on each chromosome based on all the breakpoints identified in the tumour. This was followed by a Bonferroni correction. Chromosomes with a q ≤ 0.1 were identified as having a high rate of break points. Join distribution (chromosomal and window level); test 4. In paired-end sequencing, all structural variants can be categorized into four read-pair orientations based on the direction of the + or − reads: tail-to-head (+/−, TH), headto-head (−/−), tail-to-tail (+/+) or head-to-tail (−/+, HT). Pairs in standard orientation (+/−) are considered to be a deletion-type structural variant with a TH join. Duplication-type structural variants are in the reverse-orientation −/+ and defined by a HT join. Inversions can be both in the forward (+/+) orientation or reverse (−/−) orientation. In the forward orientation, they were defined as TT and in the reverse orientation they were defined at HH. Using read-pair information for structural variants, we classified each structural variant based on their segment joins. In a catastrophic event, we expect structural variants of all four types to be present. For each region we tested this hypothesis. To initially run the test, we required at least one type of read-pair join from each of the four subtypes to be present. A multinomial test, from the EMT v1.1 package, was run to test the distribution of segment joins against an equal distribution. The regions with P > 0.05 were considered to show evidence of equal distributions of segment joins. Copy-number oscillations (chromosomal and window level); test 5. Catastrophic events typically display oscillations in copy number that vary between a few states. However, when chromothripsis is co-opted with BFB cycles as part of a single catastrophic event, there will be some segments in the event that will oscillate between limited copy number states and other segments that may appear to increase in a stepwise manner. To be categorized as a bona fide one-off event, there must be some sequential segments that retain an oscillation pattern. We required at least 4 sequential segments in any catastrophic event must oscillate between two different states. Due to polyploidization, the amplitude of the copy number step was defined as variable (1, 2 or more). Interspersed LOH (chromosomal and window level); test 6. Chromothripsis drives copy number losses, and thus copy number oscillations should correspond to interspersed loss of heterozygosity (LOH). To test for LOH, we identified all the high confidence germline heterozygous SNPs in the genome and determined the allelic ratio in the tumour sample. The distributions of allelic ratios between each sequential copy number segments were compared using a t-test. A minimum of ten positions had to be identified within each copy number segment to be processed otherwise those segments were exclude from the analysis. A Bonferroni correction test was run. Those segments in which q ≤ 0.1 were considered significantly different. To show evidence of interspersed LOH, at least four comparisons had to be made (thus at least five copy number segments had to be present in the region). At least 50% of the compared segments had to show some significant difference in the distribution of allele ratio to be classified as showing interspersed LOH. Chromosome-level analysis. Genomic regions were first evaluated at the chromosome level. For each sample, all chromosomes were independently evaluated for the above tests. For tests 2 and 3, we used copy number break points for segments where a matching structural variant could not be mapped. The importance of this point is shown in Extended Data Fig. 5c (bottom left panel; Ashpc_0008, event 2). In this case, there was a chained chromothripsis event connecting chromosomes 3 and 20. On chromosome 3, the left edge at 42.8 Mb was part of the chromothripsis event but the corresponding structural variant to this copy number loss is not mapped. This was also the case for the right edge of the chromothripsis event on chromosome 20 (7.1 Mb). In this scenario, utilization of the copy number break point was critical in the tests to decipher whether this was indeed a chromothripsis event. If copy number break points are not integrated into the analysis, such events would go undetected or be misclassified. We found that including the copy number break point was necessary to properly establish the DNA windows of chromothripsis events, especially when structural variants could not be properly mapped (discussed below). Identification of DNA rearrangement windows. The next step was to identify the borders of the catastrophic event on each chromosome. Catastrophic events typically display overlapping structural variants throughout the region of the event.
To localize the chromosomal window where the catastrophic event occurred, we selected the left and right borders of overlapping structural variant break points. Structural variants resulting in translocations were used to establish the rearrangement window when at least two independent translocations were detected between the same two chromosomes. In this manner, we could establish inter-and intra-chromosomal windows to facilitate the segregation of multi-chromosome events from single-chromosome events. Each window was flanked with 6 kb on either end. The windows that define each candidate catastrophic event were used for downstream analysis. Window-level analysis. A window was first scored on whether there were at least eight structural variants present within the window. Each window was then evaluated for tests 4-6. Males were corrected for single copy of the X chromosome by doubling the raw value. P values were derived from t-tests. A more detailed description of these data is provided in Supplementary Results.
